Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Michael G. Raab | President, CEO & Director | 21.29M | -- | 1965 |
| Ms. Elizabeth A. Grammer Esq. | Chief Legal & Administrative Officer and Secretary | 13.75M | -- | 1964 |
| Dr. Laura A. Williams M.D., M.P.H. | Chief Medical Officer | 13.68M | -- | 1964 |
| Mr. Justin A. Renz CPA, MBA | Chief Financial & Operations Officer | 12.83M | -- | 1972 |
| Mr. Joseph Reilly | Senior VP of Finance & Principal Accounting Officer | -- | -- | 1973 |
| Ms. Caitlin Lowie | Vice President of Corporate Communications & Investor Relations | -- | -- | -- |
| Mr. Mike Kelliher | Executive Vice President of Corporate Development & Strategy | -- | -- | 1977 |
| Ms. Charon Spencer Sr. | Chief Human Resources Officer | -- | -- | -- |
| Mr. David P. Rosenbaum | Chief Development Officer | 13.28M | -- | 1961 |
| Mr. Robert C. Blanks | Chief Regulatory Affairs & Quality Assurance Officer | 12.15M | -- | 1960 |
Ardelyx, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 267
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Upcoming Events
February 20, 2025 at 10:59 AM UTC
Ardelyx, Inc. Earnings Date
Recent Events
Recent Events Information Not Available